Selective COX-2 Furanone Capsule for Reduced GI Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional non-steroidal anti-inflammatory drugs (NSAIDs) inhibit both COX-1 and COX-2 enzymes, leading to gastrointestinal toxicities and fatal side effects like ulcers and hemorrhages, limiting their clinical use for long-term inflammation treatment.
Innovation Solution
A pharmaceutical composition comprising 5-{4-(aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone, a selective COX-2 inhibitor, with a 50% volume particle diameter of 3 µm to 9 µm, combined with a pharmaceutically acceptable diluent and lubricant, to enhance dissolution rate, content uniformity, and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional NSAIDs are used to inhibit COX-1 and COX-2, then anti-inflammatory efficacy is improved, but gastrointestinal toxicities and fatal side effects occur
Solution Approach 1:
The patent extracts and isolates the COX-2 inhibitory function from the dual COX-1/COX-2 inhibition mechanism of conventional NSAIDs. By developing selective COX-2 inhibitors (4,5-diaryl-3(2H)-furanone derivatives), the invention separates the therapeutic anti-inflammatory effect from the harmful gastrointestinal side effects associated with COX-1 inhibition, achieving selective COX-2 blockade without compromising gastric protection
Solution Approach 2:
The invention applies local quality by creating drugs with selective action on specific COX isoenzymes. The 4,5-diaryl-3(2H)-furanone derivatives are designed to selectively target COX-2 enzyme with high affinity while exhibiting minimal activity against COX-1, thereby localizing the pharmacological effect to the inflammatory pathway without affecting gastrointestinal homeostasis maintained by COX-1
2Productivity
If particle size is reduced to improve dissolution rate, then dissolution rate is improved, but content uniformity deteriorates
Solution Approach 1:
The patent optimizes particle size parameters within a specific range (D90 ≤ 50 μm, preferably ≤ 25 μm) to achieve the optimal balance between dissolution rate and content uniformity. This parameter optimization ensures that particles are sufficiently small for rapid dissolution while maintaining adequate size for uniform distribution and mixing in the capsule formulation
Solution Approach 2:
The invention creates a composite capsule formulation combining the furanone derivative particles with excipients including microcrystalline cellulose (as filler and flow agent), talc (as lubricant), and silicon dioxide (as anti-caking agent). This composite material system ensures both high dissolution rate and content uniformity by combining particles of optimized size with functional excipients that improve flowability and distribution
3Productivity
If particle size is reduced to improve dissolution rate, then dissolution rate is improved, but flowability deteriorates
Solution Approach 1:
The patent formulates a composite material system where microcrystalline cellulose serves as a flow-promoting excipient combined with the fine particles of the furanone derivative. This composite formulation maintains good flowability despite the reduced particle size of the active ingredient, enabling efficient capsule filling and manufacturing operations
Solution Approach 2:
The invention introduces microcrystalline cellulose and talc as intermediary substances that mediate between the fine drug particles and the capsule filling process. These excipients act as flow agents and lubricants, preventing particle aggregation and ensuring smooth flow characteristics during manufacturing while preserving the dissolution-enhancing small particle size
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a pharmaceutical composition including (i) the compound of Formula 1 described in the specification or a pharmaceutically acceptable salt thereof, (ii) a pharmaceutically acceptable diluent, and (iii) a pharmaceutically acceptable lubricant. The compound of Formula 1 or pharmaceutically acceptable salt thereof has a 50% volume particle diameter (d(0.5)) of 3 μm to 9 μm. The pharmaceutical composition of the present invention has the advantages of good stability, high dissolution rate, improved content uniformity, and excellent pharmacokinetic properties. Due to these advantages, the pharmaceutical composition of the present invention is effective in treating inflammation or pain.